title: The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology.
abstract: Anaphylaxis is a growing paediatric clinical emergency that is difficult to diagnose because a consensus definition was lacking until recently. Many European countries have no specific guidelines for anaphylaxis. This position paper prepared by the EAACI Taskforce on Anaphylaxis in Children aims to provide practical guidelines for managing anaphylaxis in childhood based on the limited evidence available. Intramuscular adrenaline is the acknowledged first-line therapy for anaphylaxis, in hospital and in the community, and should be given as soon as the condition is recognized. Additional therapies such as volume support, nebulized bronchodilators, antihistamines or corticosteroids are supplementary to adrenaline. There are no absolute contraindications to administering adrenaline in children. Allergy assessment is mandatory in all children with a history of anaphylaxis because it is essential to identify and avoid the allergen to prevent its recurrence. A tailored anaphylaxis management plan is needed, based on an individual risk assessment, which is influenced by the child's previous allergic reactions, other medical conditions and social circumstances. Collaborative partnerships should be established, involving school staff, healthcare professionals and patients' organizations. Absolute indications for prescribing self-injectable adrenaline are prior cardiorespiratory reactions, exercise-induced anaphylaxis, idiopathic anaphylaxis and persistent asthma with food allergy. Relative indications include peanut or tree nut allergy, reactions to small quantities of a given food, food allergy in teenagers and living far away from a medical facility. The creation of national and European databases is expected to generate better-quality data and help develop a stepwise approach for a better management of paediatric anaphylaxis.
authors.affiliation: Centre for Food Allergy Diagnosis and Treatment Veneto Region, Department of Pediatrics, University of Padua, Padua, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Muraro
authors.forename: G
authors.initials: G
authors.lastname: Roberts
authors.forename: A
authors.initials: A
authors.lastname: Clark
authors.forename: P A
authors.initials: PA
authors.lastname: Eigenmann
authors.forename: S
authors.initials: S
authors.lastname: Halken
authors.forename: G
authors.initials: G
authors.lastname: Lack
authors.forename: A
authors.initials: A
authors.lastname: Moneret-Vautrin
authors.forename: B
authors.initials: B
authors.lastname: Niggemann
authors.forename: F
authors.initials: F
authors.lastname: Rancé
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000707:Anaphylaxis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D004837:Epinephrine / Q000627:therapeutic use*; D005060:Europe; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant
chemical_list: D000305:Adrenal Cortex Hormones; D001993:Bronchodilator Agents; D006634:Histamine H1 Antagonists; D004837:Epinephrine